Regeneron's Ebola treatment proves superior to rival in trial
Aug 12 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O said on Monday its experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death, in a trial evaluating four treatments for infections caused by the deadly virus.
The company said the trial was ended early because its therapy, REGN-EB3, elicited a "highly statistically significant result" compared to Mapp's ZMapp, which was considered a standard-of-care treatment.
An independent data safety monitoring board ended the trial after reviewing interim mortality data from 499 patients, Regeneron said.
(Reporting by Tamara Mathias in Bengaluru; Editing by Shinjini Ganguli)
((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 1208;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.